23 results
8-K
EX-1.1
COCP
Cocrystal Pharma Inc
2 May 18
Entry into a Material Definitive Agreement
4:13pm
Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.
“Pricing Disclosure Package” means any Issuer General Use … , the Pricing Disclosure Package and the Prospectus. The Company has filed an application for the Listing of Additional Shares with the Exchange
8-K
EX-1.1
COCP
Cocrystal Pharma Inc
31 Oct 19
Entry into a Material Definitive Agreement
9:29am
Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.
“Pricing Disclosure Package” means any Issuer General Use Free Writing … , the Pricing Disclosure Package and the Prospectus. The Company has filed an application for the Listing of Additional Shares with the Exchange to list
8-K
EX-1.1
COCP
Cocrystal Pharma Inc
20 Jul 18
Entry into a Material Definitive Agreement
4:50pm
Permitted Free Writing Prospectus (as defined below) then in use (collectively, the “General Disclosure Package”), did not and will not contain any untrue … Agent expressly for use in the Prospectus or in the General Disclosure Package. The parties hereto agree that the information provided in writing
8-K
EX-1.1
COCP
Cocrystal Pharma Inc
30 Oct 19
Entry into a Material Definitive Agreement
4:38pm
), together with any Permitted Free Writing Prospectus (as defined below) then in use (collectively, the “General Disclosure Package”), did … by or on behalf of the Sales Agent expressly for use in the Prospectus or in the General Disclosure Package. The parties hereto agree that the information provided
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
-IND briefing package to the FDA for intranasal/pulmonary CDI-45205 for the treatment of COVID-19 and sets goal of initiating IND-enabling study … the U.S. Food and Drug Administration (FDA) by mid-December on our pre-IND briefing package for our intranasal/pulmonary-delivered SARS-CoV-2
8-K
EX-10.1
8m06mh8d
13 Jan 12
Unregistered Sales of Equity Securities
12:00am
8-K
EX-99.1
p6qh015ga zlrs
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-10.11
i3dr 5gfgfk4p
7 Jul 11
Acquires Biozone Laboratories, Inc. and Related Companies
12:00am
8-K
EX-99.1
hjhlb6y6cf3 hm
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
EX-10.1
fnpr9ivfw2bs8 w9e
18 Apr 13
Unregistered Sales of Equity Securities
12:00am
8-K
EX-99.1
9cf42q qot
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
424B7
vzo8cs0svrr dl3i182
26 Feb 13
Prospectus with selling stockholder info
12:00am